BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...
Novo Nordisk A/S is back on the hunt for deals to boost its obesity portfolio after losing US biotech Metsera Inc. in a ...
Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...
M+C Saatchi North America is turning to a longtime pharma pro to serve as its inaugural medical advisor. | M+C Saatchi North ...
And not only were we fortunate enough to score TWO exclusive clips from this highly anticipated hour (as well as Scott Wolf’s ...
Biopharma stocks may rally in 2026 as M&A heats up and drug pricing uncertainty fades—see why UBS expects big pharma to buy ...
24/7 Wall St. on MSN
Fed Governor Wants Huge Rate Cuts This Year: 5 High-Yield Dividend Stocks to Buy Today
These five high-yield dividend stocks with solid upside potential and Buy ratings make sense for growth and income investors ...
In this episode, Caroline Michie discusses key data from ASCENT-3, TROPION2, and PLANeT, and how these findings translate ...
Saharsh Davuluri, Neuland Labs, covers M&A blending, geopolitical shifts, and supply chain de-risking in this look back at ...
The University of Pennsylvania, biotech firm BioNTech, and Osage University Partners, a venture capital firm in Bala Cynwyd, ...
Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback